New drug combo aims to stop liver cancer from coming back after ablation

This study tests whether adding the drug lenvatinib before and after a standard tumor-burning procedure (ablation) can prevent liver cancer from returning in patients at high risk of recurrence. About 32 adults with early-stage liver cancer and certain aggressive features will receive lenvatinib for a short time before ablation and then for up to a year after. The goal is to see if this approach improves the chance of being cancer-free one year later.